Mometasone furoate

Results: 85



#Item
1IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION ASMANEX® Twisthaler® Mometasone Furoate Dry Powder Inhaler

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION ASMANEX® Twisthaler® Mometasone Furoate Dry Powder Inhaler

Add to Reading List

Source URL: www.merck.ca

Language: English - Date: 2018-02-13 14:47:06
    2PROPEL® mini (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE:

    PROPEL® mini (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE:

    Add to Reading List

    Source URL: propelopens.com

    - Date: 2016-06-09 16:50:32
      3PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE:

      PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE:

      Add to Reading List

      Source URL: propelopens.com

      Language: English - Date: 2016-04-01 12:43:40
      4Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL

      Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL

      Add to Reading List

      Source URL: propelopens.com

      Language: English - Date: 2016-07-08 12:30:12
      5Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica

      Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica

      Add to Reading List

      Source URL: propelopens.com

      Language: English - Date: 2016-06-01 10:43:20
      6Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis Company Also Recognized in Deloitte’s 2015 Technology Fast 500 MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a comp

      Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis Company Also Recognized in Deloitte’s 2015 Technology Fast 500 MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a comp

      Add to Reading List

      Source URL: propelopens.com

      Language: English - Date: 2015-11-17 11:28:47
      7Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants Savings Associated with Reduced Post-Operative Interventions Support Use of PROPEL MENLO PARK, Calif., Novembe

      Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants Savings Associated with Reduced Post-Operative Interventions Support Use of PROPEL MENLO PARK, Calif., Novembe

      Add to Reading List

      Source URL: propelopens.com

      Language: English - Date: 2015-11-10 10:16:52
      8Intersect ENT Announces Publication of Position Statement from AAO-HNS on Use of Biomaterials Statement Supports Use of PROPEL, the Only FDA-Approved Biomaterial Used to Improve Patient Outcomes in Sinus Procedures Menlo

      Intersect ENT Announces Publication of Position Statement from AAO-HNS on Use of Biomaterials Statement Supports Use of PROPEL, the Only FDA-Approved Biomaterial Used to Improve Patient Outcomes in Sinus Procedures Menlo

      Add to Reading List

      Source URL: propelopens.com

      Language: English - Date: 2015-10-21 16:28:17
      9Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany Decision Represents Early Step in Building the Company’s Foundation Internationally MENLO PARK, Calif.—January 29, 2016—Intersect

      Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany Decision Represents Early Step in Building the Company’s Foundation Internationally MENLO PARK, Calif.—January 29, 2016—Intersect

      Add to Reading List

      Source URL: propelopens.com

      Language: English - Date: 2016-02-02 07:14:47
      10Intersect ENT Announces FDA Approval of Additional Indication for PROPEL® Mini Sinus Implant PROPEL Mini Now Indicated to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—March 23, 2016—Intersect ENT, In

      Intersect ENT Announces FDA Approval of Additional Indication for PROPEL® Mini Sinus Implant PROPEL Mini Now Indicated to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—March 23, 2016—Intersect ENT, In

      Add to Reading List

      Source URL: propelopens.com

      Language: English - Date: 2016-03-23 16:11:00